Cargando…

A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

BACKGROUND: Transthyretin amyloidosis (ATTR amyloidosis) is a progressive, multisystemic, life-threatening disease resulting from the deposition of variant or wild-type (ATTRwt amyloidosis) transthyretin amyloid fibrils in various tissues and organs. METHODS: Established in 2007, the Transthyretin A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gentile, Luca, Coelho, Teresa, Dispenzieri, Angela, Conceição, Isabel, Waddington-Cruz, Márcia, Kristen, Arnt, Wixner, Jonas, Diemberger, Igor, Gonzalez-Moreno, Juan, Cariou, Eve, Maurer, Mathew S., Planté-Bordeneuve, Violaine, Garcia-Pavia, Pablo, Tournev, Ivailo, Gonzalez-Costello, Jose, Duarte, Alejandra Gonzalez, Grogan, Martha, Mazzeo, Anna, Chapman, Doug, Gupta, Pritam, Glass, Oliver, Amass, Leslie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636983/ https://www.ncbi.nlm.nih.gov/pubmed/37946256 http://dx.doi.org/10.1186/s13023-023-02962-5

Ejemplares similares

Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update
por: Dispenzieri, Angela, et al.
Publicado: (2022)

Sex Differences in Wild-Type Transthyretin Amyloidosis: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Campbell, Courtney M., et al.
Publicado: (2022)

Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Waddington-Cruz, Márcia, et al.
Publicado: (2021)

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)

Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS
por: Gentile, Luca, et al.
Publicado: (2021)

Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Waddington‐Cruz, Márcia, et al.
Publicado: (2021)

THAOS: Gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease
por: Wixner, Jonas, et al.
Publicado: (2014)

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021)

Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
por: Kristen, Arnt V., et al.
Publicado: (2017)

Patisiran treatment in patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy after liver transplantation
por: Schmidt, Hartmut H., et al.
Publicado: (2022)

Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy
por: Gendre, Thierry, et al.
Publicado: (2019)

Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis
por: Merlini, Giampaolo, et al.
Publicado: (2013)

Non-parametric estimation of survival in age-dependent genetic disease and application to the transthyretin-related hereditary amyloidosis
por: Alarcon, Flora, et al.
Publicado: (2018)

Guideline of transthyretin-related hereditary amyloidosis for clinicians
por: Ando, Yukio, et al.
Publicado: (2013)

Screening for hereditary transthyretin amyloidosis in Bulgaria
por: Nakov, Radislav, et al.
Publicado: (2021)

A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey
por: González-Moreno, Juan, et al.
Publicado: (2021)

Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Mundayat, Rajiv, et al.
Publicado: (2018)

Gene expression profile in hereditary transthyretin amyloidosis: differences in targeted and source organs
por: Norgren, Nina, et al.
Publicado: (2014)

Fecal calprotectin levels are elevated in transthyretin amyloidosis patients with gastrointestinal manifestations
por: Nakov, Radislav, et al.
Publicado: (2020)

A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers
por: Olsson, Malin, et al.
Publicado: (2010)

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2013)

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
por: Adams, David, et al.
Publicado: (2016)

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2016)

Cardiac involvement and clinical follow up of patients with hereditary transthyretin related amyloidosis associated with Glu89Gln mutation
por: Gospodinova, Mariana, et al.
Publicado: (2015)

Glu89Gln transthyretin-related amyloidosis in Italy and Bulgaria: does geographic area influence phenotype beyond the shared mutation?
por: Gagliardi, Christian, et al.
Publicado: (2015)

Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy
por: González‐Duarte, Alejandra, et al.
Publicado: (2020)

Estimating the global prevalence of transthyretin familial amyloid polyneuropathy
por: Schmidt, Hartmut H., et al.
Publicado: (2018)

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy
por: Schmidt, Hartmut H.‐J., et al.
Publicado: (2016)

“Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy
por: Conceição, Isabel, et al.
Publicado: (2016)

Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update
por: Brannagan, Thomas H., et al.
Publicado: (2022)

Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy
por: Waddington Cruz, Márcia, et al.
Publicado: (2016)

Early intervention with tafamidis provides long-term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy
por: Waddington-Cruz, Marcia, et al.
Publicado: (2015)

Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy
por: Maestro‐Benedicto, Alba, et al.
Publicado: (2022)

Case Report: Transthyretin Glu54Leu—a rare mutation with predominant cardiac phenotype
por: Gospodinova, Mariana, et al.
Publicado: (2023)

Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms
por: Gonzalez-Lopez, Esther, et al.
Publicado: (2022)

Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series
por: Waddington-Cruz, Márcia, et al.
Publicado: (2019)

Study of the parent-of-origin effect in monogenic diseases with variable age of onset. Application on ATTRv
por: Alarcon, Flora, et al.
Publicado: (2023)

Delayed small bowel octreotide response in patients with hereditary transthyretin amyloidosis
por: Jonas, Wixner, et al.
Publicado: (2015)

Loss of gastric interstitial cells of Cajal in patients with hereditary transthyretin amyloidosis
por: Wixner, Jonas, et al.
Publicado: (2013)

Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy
por: Damy, Thibaud, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t3v731i76f9ar8mh4a8uom8p4i